Last Update 27 Mar 26

NTLA: Clinical Hold Resolution Will Reopen ATTR Phase 3 Value Opportunity

Analysts lifted their price targets on Intellia Therapeutics toward a range of about $15 to $48 after the FDA removed clinical holds on the MAGNITUDE program, citing improved clarity on safety, updated trial protocols, and a higher assumed probability of success for nexiguran ziclumeran in ATTR indications.

Analyst Commentary

Research updates following the FDA's decision cluster around how much value investors should assign to nexiguran ziclumeran in transthyretin amyloidosis and how execution risk in Phase 3 might affect Intellia Therapeutics' longer term profile.

Bullish Takeaways

Bullish analysts see the FDA lifting clinical holds on the MAGNITUDE and MAGNITUDE-2 programs as removing a key overhang. They link this to higher assumed probabilities of success and price targets that now span roughly US$15 to US$48.
Several price target increases in the mid to high US$20s, along with rating upgrades, reflect the view that nexiguran ziclumeran in ATTR cardiomyopathy could once again be a major value driver if Phase 3 enrollment and execution proceed as planned.
Some analysts point to updated trial protocols, including tighter exclusion criteria and more detailed monitoring, as improving visibility on safety management. They see this as helpful for de risked execution and potential uptake if approved.
Comments that the clinical hold resolution was based on efficacy and safety data from about 650 patients are interpreted by bullish analysts as reinforcing the overall risk benefit profile. This feeds into their more constructive stance on the equity story.

Bearish Takeaways

More cautious analysts keep neutral or equal weight style ratings even with higher price targets. In their view, current valuation already reflects meaningful expectations for nexiguran ziclumeran and the broader ATTR franchise.
Concerns around liver related safety, including the need for enhanced monitoring and short term steroid use in response to lab changes, are seen as ongoing execution risks that could influence physician comfort and real world demand if the therapy reaches market.
The presence of existing treatment options that are described as safe leads more bearish analysts to flag tolerability as a key watch point. They note that any perceived safety trade off could limit share capture even if clinical efficacy is strong.
Some commentary suggests that a relatively modest share price reaction to the clinical hold lift reflects investor hesitation around longer term demand assumptions. This keeps more cautious analysts from assigning higher valuation multiples at this stage.

What's in the News

The FDA removed the clinical hold on the MAGNITUDE Phase 3 trial of nexiguran ziclumeran for transthyretin amyloidosis with cardiomyopathy, following agreement on enhanced liver monitoring, short-term steroid guidance, and exclusion of certain patients with liver abnormalities (Key Developments).
The FDA previously removed the clinical hold on the MAGNITUDE 2 Phase 3 trial in hereditary transthyretin amyloidosis with polyneuropathy, with Intellia aligning on study modifications that include enhanced liver safety monitoring and working with global trial sites to resume enrollment (Key Developments).
At the 2026 AAAAI Annual Meeting, Intellia reported pooled Phase 1/2 data for lonvoguran ziclumeran in hereditary angioedema. A one-time 50 mg dose was associated with deep and durable reductions in plasma kallikrein and a mean 96% reduction in attack rate across 32 patients, with 31 patients attack-free and off long-term prophylaxis at data cutoff (Key Developments).
Additional AAAAI data showed that 86% of patients with more than 6 months of follow-up after a one-time 50 mg lonvoguran ziclumeran dose were attack-free and off long-term prophylaxis for more than 6 months, a timeframe patients described as clinically meaningful (Key Developments).
Survey data presented at AAAAI highlighted that many hereditary angioedema patients on chronic therapies still report regular attacks, with most respondents indicating that removing lifetime chronic medication use and improving efficacy are top priorities. This aligns with the one-time treatment goal for lonvoguran ziclumeran (Key Developments).

Valuation Changes

Fair Value: $25.29 is unchanged, with the updated estimate matching the prior figure.
Discount Rate: 7.15% has edged lower to about 7.15%, reflecting a very small adjustment in the risk rate used.
Revenue Growth: 106.26% remains effectively the same, with no material change in the growth assumption applied.
Net Profit Margin: 10.54% has risen to 14.77%, indicating a higher assumed level of profitability once the business scales.
Future P/E: 71.57x has fallen to 51.05x, pointing to a lower valuation multiple applied to projected earnings.

16 views

Key Takeaways

Accelerated clinical progress and expanding market opportunities position Intellia for earlier commercialization and significant long-term revenue growth.
Improved financial discipline and strong clinical validation support sustainable margins, enhanced payer acceptance, and recurring revenue from commercialization and partnerships.
Competitive pressures, high development costs, pipeline concentration, and reimbursement barriers threaten Intellia's growth, profitability, and ability to sustain its technological edge over time.

Catalysts

About Intellia Therapeutics

A clinical-stage gene editing company, focuses on the development of curative genome editing treatments.What are the underlying business or industry changes driving this perspective?

Growing patient and physician enthusiasm for Intellia's lead in vivo CRISPR therapies is driving faster-than-expected enrollment across multiple late-stage clinical trials (including an expanded 1,200-patient ATTR cardiomyopathy study and strong uptake in HAE), positioning the company to achieve meaningful clinical readouts and regulatory milestones ahead of prior guidance-this advances timelines to potential commercialization, driving long-term revenue growth prospects.
The sustained expansion of the addressable market for Intellia's programs is reinforced by demographic trends-especially aging populations and the continued rise in genetic and chronic conditions like ATTR amyloidosis and HAE-supporting higher future patient volumes and underpinning potential multi-launch revenue inflection points.
Improving financial discipline, as evidenced by successful restructuring, declining GAAP operating expenses (~10% reduction YoY), and a robust cash runway into the first half of 2027, enables Intellia to absorb increased R&D investment, advance pipeline expansion, and build out commercial infrastructure without dilutive fundraising, supporting protection of net margins and improving future earnings visibility.
Strengthening real-world validation of the company's platform-with mature clinical data showing durable, attack-free results in HAE and deep TTR reductions plus positive functional outcomes in ATTR-should bolster pricing power, enhance payer acceptance, and create leverage for value-based reimbursement, directly benefiting gross margins and long-term profitability.
Rapid technological and regulatory advancements in gene-editing-including increased healthcare investments, accelerating review pathways, and support for first-in-class CRISPR therapies-create a favorable environment for Intellia's platform to secure approvals, forge additional partnership/licensing opportunities, and achieve sustainable, recurring non-dilutive revenues through both commercialization and collaborations, increasing top-line growth and earnings potential.

Intellia Therapeutics Earnings and Revenue Growth

Intellia Therapeutics Future Earnings and Revenue Growth

Assumptions

How have these above catalysts been quantified?

Analysts are assuming Intellia Therapeutics's revenue will grow by 106.3% annually over the next 3 years.
Analysts are not forecasting that Intellia Therapeutics will become profitable in next 3 years. To represent the Analyst Price Target as a Future PE Valuation we will estimate Intellia Therapeutics's profit margin will increase from -609.9% to the average US Biotechs industry of 14.8% in 3 years.
If Intellia Therapeutics's profit margin were to converge on the industry average, you could expect earnings to reach $87.7 million (and earnings per share of $0.61) by about March 2029, up from -$412.7 million today.
In order for the above numbers to justify the price target of the analysts, the company would need to trade at a PE ratio of 51.3x on those 2029 earnings, up from -3.8x today. This future PE is greater than the current PE for the US Biotechs industry at 15.7x.
Analysts expect the number of shares outstanding to grow by 7.0% per year for the next 3 years.
To value all of this in today's terms, we will use a discount rate of 7.15%, as per the Simply Wall St company report.

Risks

What could happen that would invalidate this narrative?

Mounting competition from alternative gene therapy and RNAi approaches-including established and newly launched therapies in ATTR amyloidosis and HAE-could limit nex-z and lonvo-z's market share and weaken Intellia's pricing power, impacting long-term revenue growth and gross margins.
Reliance on major late-stage clinical trial results for limited lead programs (nex-z, lonvo-z) creates revenue concentration risk; any regulatory, clinical, or safety setbacks could significantly delay or diminish future earnings and long-term profitability.
High R&D expenses and ongoing cash burn, combined with no near-term commercial product revenues, raise the risk of shareholder dilution or funding constraints, potentially pressuring net margins and earnings despite current cash runway guidance.
Payer scrutiny and reimbursement challenges for costly, potentially one-time gene-editing therapies-especially in crowded indications-could limit uptake, slow commercial ramp, and jeopardize expected revenue streams.
Advances in other gene editing or treatment modalities (such as prime editing, base editing, or more effective RNAi) could erode Intellia's technological lead, making its CRISPR platform less differentiated over the long term, which would negatively affect revenue growth and long-term valuation.

Valuation

How have all the factors above been brought together to estimate a fair value?

The analysts have a consensus price target of $25.29 for Intellia Therapeutics based on their expectations of its future earnings growth, profit margins and other risk factors.
However, there is a degree of disagreement amongst analysts, with the most bullish reporting a price target of $106.0, and the most bearish reporting a price target of just $5.0.
In order for you to agree with the analysts, you'd need to believe that by 2029, revenues will be $593.8 million, earnings will come to $87.7 million, and it would be trading on a PE ratio of 51.3x, assuming you use a discount rate of 7.1%.
Given the current share price of $13.24, the analyst price target of $25.29 is 47.6% higher.
We always encourage you to reach your own conclusions though. So sense check these analyst numbers against your own assumptions and expectations based on your understanding of the business and what you believe is probable.

Have other thoughts on Intellia Therapeutics?

Create your own narrative on this stock, and estimate its Fair Value using our Valuator tool.

Create Narrative

How well do narratives help inform your perspective?

Disclaimer

AnalystConsensusTarget is a tool utilizing a Large Language Model (LLM) that ingests data on consensus price targets, forecasted revenue and earnings figures, as well as the transcripts of earnings calls to produce qualitative analysis. The narratives produced by AnalystConsensusTarget are general in nature and are based solely on analyst data and publicly-available material published by the respective companies. These scenarios are not indicative of the company's future performance and are exploratory in nature. Simply Wall St has no position in the company(s) mentioned. Simply Wall St may provide the securities issuer or related entities with website advertising services for a fee, on an arm's length basis. These relationships have no impact on the way we conduct our business, the content we host, or how our content is served to users. The price targets and estimates used are consensus data, and do not constitute a recommendation to buy or sell any stock, and they do not take account of your objectives, or your financial situation. Note that AnalystConsensusTarget's analysis may not factor in the latest price-sensitive company announcements or qualitative material.

Paused Trials Will Drive Rebound After Resolution Of Safety Concerns